1 – 16 of 16
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept : Results from the international TOCERRA and PANABA observational collaborative studies
(
- Contribution to journal › Article
-
Mark
Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice
(
- Contribution to journal › Article
- 2023
-
Mark
Increased Galectin-9 Levels Correlate with Disease Activity in Patients with DMARD-Naïve Rheumatoid Arthritis and Modulate the Secretion of MCP-1 and IL-6 from Synovial Fibroblasts
(
- Contribution to journal › Article
-
Mark
Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis : results from five Nordic biologics registries
(
- Contribution to journal › Article
-
Mark
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
(
- Contribution to journal › Scientific review
-
Mark
Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis : Results from the EuroSpA Research Collaboration Network
(
- Contribution to journal › Article
-
Mark
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis : 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial
(
- Contribution to journal › Article
- 2022
-
Mark
Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs : Results from four Nordic countries
(
- Contribution to journal › Article
-
Mark
One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis : Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses
(
- Contribution to journal › Article
-
Mark
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors : Data from the EuroSpA collaboration
(
- Contribution to journal › Article
- 2020
-
Mark
Active conventional treatment and three different biological treatments in early rheumatoid arthritis : Phase IV investigator initiated, randomised, observer blinded clinical trial
(
- Contribution to journal › Article
- 2019
-
Mark
Imputing missing data of function and disease activity in rheumatoid arthritis registers : What is the best technique?
(
- Contribution to journal › Article
- 2017
-
Mark
Cancer risk in patients with spondyloarthritis treated with TNF inhibitors : A collaborative study from the ARTIS and DANBIO registers
(
- Contribution to journal › Article
-
Mark
The effect of an intensive smoking cessation intervention on disease activity in patients with rheumatoid arthritis : Study protocol for a randomised controlled trial
(
- Contribution to journal › Article
-
Mark
Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the “pan-European registry collaboration for abatacept (PANABA)
(
- Contribution to journal › Article
- 2011
-
Mark
New remission criteria for RA: 'modern times' in rheumatology--not a silent film, rather a 3D movie.
(
- Contribution to journal › Article